Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Shares Sold by Acadian Asset Management LLC

Acadian Asset Management LLC reduced its position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) by 95.5% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 119,370 shares of the biotechnology company’s stock after selling 2,519,317 shares during the period. Acadian Asset Management LLC owned about 2.48% of Atara Biotherapeutics worth $1,013,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Delap Wealth Advisory LLC bought a new position in shares of Atara Biotherapeutics during the first quarter valued at approximately $29,000. BNP Paribas Financial Markets boosted its position in Atara Biotherapeutics by 29.3% during the 1st quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock valued at $266,000 after purchasing an additional 86,842 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Atara Biotherapeutics by 8,916.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock worth $3,442,000 after buying an additional 4,903,159 shares during the last quarter. Finally, Redmile Group LLC grew its stake in Atara Biotherapeutics by 1.7% during the 1st quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock worth $6,429,000 after buying an additional 156,863 shares during the last quarter. 70.90% of the stock is currently owned by institutional investors.

Atara Biotherapeutics Trading Down 7.5 %

ATRA stock opened at $7.87 on Thursday. The firm’s 50-day moving average is $8.74 and its two-hundred day moving average is $12.71. The company has a market capitalization of $37.91 million, a price-to-earnings ratio of -0.15 and a beta of 0.50. Atara Biotherapeutics, Inc. has a 52 week low of $4.96 and a 52 week high of $49.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) EPS for the quarter, missing analysts’ consensus estimates of ($1.56) by ($1.54). The company had revenue of $28.64 million for the quarter, compared to analyst estimates of $48.30 million. On average, equities research analysts predict that Atara Biotherapeutics, Inc. will post -12.09 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on ATRA shares. The Goldman Sachs Group reduced their price target on shares of Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a report on Wednesday, July 17th. Mizuho raised shares of Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and reduced their target price for the company from $25.00 to $18.00 in a research note on Friday, August 16th. HC Wainwright restated a “neutral” rating on shares of Atara Biotherapeutics in a research note on Wednesday, August 21st. Canaccord Genuity Group reiterated a “buy” rating and set a $13.00 price objective on shares of Atara Biotherapeutics in a research report on Tuesday, August 13th. Finally, StockNews.com initiated coverage on Atara Biotherapeutics in a research report on Wednesday, June 26th. They issued a “hold” rating on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Atara Biotherapeutics currently has a consensus rating of “Hold” and a consensus price target of $185.50.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.